BioMedicine
Volume 10

Issue 1

Article 5

2020

Hyperuricemia might be an early manifestation of undiagnosed
adult leukemia in a population-based cohort study

Follow this and additional works at: https://www.biomedicinej.com/biomedicine
Part of the Life Sciences Commons, and the Medical Sciences Commons

This work is licensed under a Creative Commons Attribution 4.0 License.
Recommended Citation
Lai, Shih-Wei; Lin, Cheng-Li; and Liao, Kuan-Fu (2020) "Hyperuricemia might be an early manifestation of
undiagnosed adult leukemia in a population-based cohort study," BioMedicine: Vol. 10 : Iss. 1 , Article 5.
DOI: 10.37796/2211-8039.1004

This Original Articles is brought to you for free and open access by BioMedicine. It has been accepted for inclusion
in BioMedicine by an authorized editor of BioMedicine.

ORIGINAL ARTICLE

Hyperuricemia might be an early manifestation of
undiagnosed adult leukemia in a population-based
cohort study
Shih-Wei Lai a,b, Cheng-Li Lin a,c, Kuan-Fu Liao d,e,*
a

College of Medicine, China Medical University, Taichung, Taiwan
Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan
c
Management Ofﬁce for Health Data, China Medical University Hospital, Taichung, Taiwan
d
College of Medicine, Tzu Chi University, Hualien, Taiwan
e
Division of Hepatogastroenterology, Department of Internal Medicine, Taichung Tzu Chi General Hospital, Taichung, Taiwan
b

Abstract
Background/objective: No published population-based study investigates the association between hyperuricemia and
undiagnosed adult leukemia in Taiwan. The aim of the study was to investigate whether hyperuricemia might be an
early manifestation of undiagnosed adult leukemia in Taiwan.
Methods: A population-based cohort study was conducted to analyze the database of the Taiwan National Health
Insurance Program. There were 47708 subjects aged 20 to 84 years with newly diagnosed hyperuricemia as the hyperuricemia group from 2000 to 2013, and 190832 randomly selected subjects without hyperuricemia as the non-hyperuricemia group. The hyperuricemia group and the non-hyperuricemia group were followed for one year to estimate the
incidence of new diagnosis of leukemia.
Results: The overall incidence of leukemia was 1.32-fold higher in the hyperuricemia group than the non-hyperuricemia group (0.74 versus 0.55 per 10000 person-months, 95% conﬁdence interval 1.28-1.37). The incidence rate ratio of
leukemia was statistically higher in the ﬁrst 3 months of hyperuricemia diagnosis (incidence rate ratio 4.05).
Conclusion: Adults with hyperuricemia have a higher incidence of being diagnosed with leukemia than those without
hyperuricemia. Hyperuricemia might be an early manifestation of undiagnosed adult leukemia. Clinicians should check
the complete blood count with differential to detect the possibility of leukemia when adults present with hyperuricemia.
Keywords: adult, hyperuricemia, leukemia, Taiwan National Health Insurance Program

1. Introduction

L

eukemia is a cancer of blood, arising from
blood cell types. Leukemia was as the ninth
commonest cancer in the world in 2016 [1]. There
were about 467000 new cases of leukemia, which
accounted for 2.71% of 17228000 new cancer cases
in the world in 2016 [1]. Leukemia ranked the
thirteenth leading cause of cancer death in
Taiwan in 2018 [2]. There were 1096 deaths due to

leukemia, which accounted for 2.25% of 48784
cancer deaths in Taiwan in 2018 [2].
Early manifestations of leukemia before diagnosis might be vague or non-speciﬁc, including
fatigue, fever, pallor, bleeding tendency, body
weight loss, night sweats, insomnia, loss of appetite, ophthalmic involvement, gingival enlargement, and others [3-13]. When leukemia is treated
with chemotherapy, hyperuricemia might develop
due to rapid turnover of tumor cells [14-25]. Yet, no
systemic analysis focuses on the association
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between hyperuricemia and undiagnosed adult
leukemia.
The prevalence of hyperuricemia was high in the
general population [26-31], but little is known
regarding the association hyperuricemia and undiagnosed adult leukemia in Taiwan. If hyperuricemia
is an early manifestation of undiagnosed adult leukemia, these undiagnosed leukemia patients might
have a chance to be early detected and they might
have a chance to be early treated. Therefore, a
population-based cohort study was conducted to
investigate this issue.

hyperuricemia group were matched with sex, age
(every 5-year interval), and the year of index date.
Subjects with a history of any cancer before the
index date were excluded from the study.

2. Materials and methods

We compared the differences of sex and age between the hyperuricemia group and the non-hyperuricemia group by the Chi-square test for
categorized variables and the t-test for continuous
variables. The incidence of leukemia was estimated
as the event number of leukemia detected during
the follow-up period, divided by the total follow-up
person-months for each group. The incidences of
leukemia stratiﬁed by sex, age, and follow-up period
between the hyperuricemia group and the non-hyperuricemia group were estimated. The incidence
rate ratio (IRR) and the 95% conﬁdence interval (CI)
of leukemia in the hyperuricemia group versus the
non-hyperuricemia group were estimated. All analyses were performed by the SAS 9.2 version (SAS
Institute Inc., Carey, North Carolina, USA). The results were considered statistically signiﬁcant when
two-tailed P values were <0.05.

2.3. Major outcome
The major outcome was a new diagnosis of leukemia (ICD-9 codes 204-208) during the follow-up
period. All study subjects were followed for one year.
2.4. Statistical analysis

2.1. Study design and data source
A population-based cohort study was conducted to
analyze the database of the Taiwan National Health
Insurance Program. The program was launched in
March 1, 1995, and it has covered about 99.7% of 23
million people living in Taiwan [32, 33]. The database
included sex, date of birth, and information on
ambulatory care, hospitalization care, dental care,
emergency care, and prescribed medications [34-40].
2.2. Selection of subjects
Subjects aged 20 to 84 years with newly diagnosed
hyperuricemia and/or with a new attack of gout
from 2000 to 2013 were selected as the hyperuricemia group (the International Classiﬁcation of Diseases 9th Revision, ICD-9 codes 790.6 and 274). For
each subject in the hyperuricemia group, approximately 4 subjects without hyperuricemia and gout
were randomly selected as the non-hyperuricemia
group. The index date was deﬁned as the date of
subjects being diagnosed with hyperuricemia or
gout. The hyperuricemia group and the non-

3. Results
3.1. Baseline information of the study population
Table 1 reveals the baseline information of the
study population. There were 47708 subjects in the
hyperuricemia group and 190832 subjects in the

Table 1. Baseline characteristics of the study population.
Variable

Sex
Female
Male
Age group (years)
20-39
40-64
65-84
Age (years), mean ± standard
deviationb

Hyperuricemia N ¼ 47708

Non-hyperuricemia
N ¼ 190832
n

(%)

n

(%)

61014
129818

(32.0)
(68.0)

16154
31554

(33.9)
(66.1)

61049
97551
32232
48.6 ± 15.4

(32.0)
(51.1)
(16.9)

15497
23791
8420
48.6 ± 15.5

(32.5)
(49.9)
(17.6)

P valuea

0.001

0.001

Data are presented as the number of subjects in each group with percentages given in parentheses.
a
Chi-square test and.
b
t-test comparing the hyperuricemia group and the non-hyperuricemia group.

0.27
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Table 2. Incidence of leukemia stratiﬁed by sex, age, and follow-up period between the hyperuricemia group and the non-hyperuricemia group.
Non-hyperuricemia
Variable

N

Hyperuricemia
Event

All
190832
126
Sex
Female
61014
50
Male
129818
76
Age group (years)
20e39
61049
21
40e64
97551
68
65-84
32232
37
Follow-up period (months)
3
190832
4
3-12
190306
122
a
b

Person-months

Incidencea

N

Event

Person-months

Incidencea

IRRb

(95% CI)

2276984

0.55

47708

42

571180

0.74

1.32

(1.28, 1.37)

728563
1548421

0.69
0.49

16154
31554

16
26

193388
377791

0.83
0.69

1.19
1.42

(1.12, 1.26)
(1.36, 1.48)

728860
1167195
380929

0.29
0.58
0.97

15497
23791
8420

10
17
15

185809
285081
100291

0.54
0.60
1.50

1.88
1.04
1.54

(1.77, 1.99)
(0.98, 1.09)
(1.42, 1.66)

571701
1705283

0.07
0.72

47708
47666

4
38

143077
428103

0.28
0.89

4.05
1.23

(3.90, 4.20)
(1.19, 1.28)

Incidence rate: per 10000 person-months.
IRR (incidence rate ratio, adjusted for sex and age): hyperuricemia versus non-hyperuricemia (95% conﬁdence interval).

non-hyperuricemia group. The mean ages (standard
deviation) of the study subjects were 48.6 (15.5)
years for the hyperuricemia group and 48.6 (15.4)
years for the non-hyperuricemia group, without
statistical signiﬁcance (t-test, P ¼ 0.27).
3.2. Incidence of leukemia stratiﬁed by sex age, and
follow-up period
Table 2 reveals that after adjusted for sex and age,
the overall incidence of leukemia was 1.32-fold
higher in the hyperuricemia group than that in the
non-hyperuricemia group (0.74 versus 0.55 per
10000 person-months, 95% CI 1.28-1.37). The incidences of leukemia, as stratiﬁed by sex, age, and
follow-up period, were all statistically higher in the
hyperuricemia group than those in the non-hyperuricemia group. Subjects aged 65 to 84 years in the
hyperuricemia group had a particularly higher
incidence of leukemia (1.5 per 10000 personmonths). The incidence rate ratio of leukemia was
statistically higher in the ﬁrst 3 months of follow-up
(incidence 0.28 versus 0.07 per 10000 personmonths, incidence rate ratio 4.05, 95% CI 3.90-4.20).
The incidence rate ratio was reduced to 1.23 during
3-12 months of follow-up (incidence 0.89 versus 0.72
per 10000 person-months, 95% CI 1.19-1.28).

patients in our study were new cases. The diagnosis of
hyperuricemia in the study was really prior to the
conﬁrmed diagnosis of leukemia. Therefore, hyperuricemia is less likely to be secondary to chemotherapy for leukemia or other cancers.
Although not unexpected ﬁndings, we noted that
the overall incidence of leukemia was 1.32-fold
higher in the hyperuricemia group than that in the
non-hyperuricemia group. The incidence rate ratio
of leukemia was statistically higher in the ﬁrst
3 months (incidence rate ratio 4.05). Although the
outcome number was small (only 42 leukemia patients), our ﬁndings highlight that hyperuricemia
might be an early manifestation of undiagnosed
adult leukemia, particularly within three months of
hyperuricemia diagnosis.
We reviewed the relevant literature to explain the
association between hyperuricemia and undiagnosed adult leukemia. Leukemia cells have a tendency of rapid turnover, which leads to rapid
breakdown of these tumor cells and subsequent
hyperuricemia [14-17, 22]. Because early manifestations of leukemia before conﬁrmed diagnosis might
be vague or non-speciﬁc, it is difﬁcult to early diagnose leukemia. We suggest that clinicians should
check the complete blood count with differential to
detect the possibility of leukemia when adults present with hyperuricemia.

4. Discussion
To the best of our knowledge, this is the ﬁrst population-based study to investigate the association between hyperuricemia and undiagnosed adult
leukemia in Taiwan. No other study can be compared
with each other. In order to reduce the biased results in
our study, subjects with a history of any cancer before
the index date were excluded from the study. All study
subjects were followed until leukemia was newly
diagnosed or for one year. Therefore, leukemia

5. Limitation
Several limitations of the study should be discussed. First, due to the inherent limitation of the
database, other manifestations of leukemia before
conﬁrmed diagnosis were not documented. We
could not determine hyperuricemia or other manifestations caming ﬁrst. During disease progression
of different stages, leukemia patients would have
different manifestations, but our study could not

verify it. Second, due to the eligible number of
leukemia patients being small, we could not make a
comparative analysis between acute and chronic
leukemia. We could only analyze the association
between hyperuricemia and the overall leukemia.
Moreover, it indicates a future research direction.
Third, In view of the availability of the Taiwan's
medical care, it is not necessary to spend one year to
diagnose leukemia since the onset of leukemiarelated manifestations. That was why subjects in our
study were only followed for one year.
We conclude that adults with hyperuricemia have
a higher incidence of being diagnosed with leukemia than those without hyperuricemia. Hyperuricemia might be an early manifestation of
undiagnosed adult leukemia. Clinicians should
check the complete blood count with differential to
detect the possibility of leukemia when adults present with hyperuricemia.
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